Engineering an IL2-Free, Potent & Persistent TIL With Regulated Membrane-Bound IL15
Time: 12:30 pm
day: Day Two
Details:
• Sidestepping capillary leak syndrome associated toxicity and Treg effects
• Removing the need for toxic and costly IL2 therapy associated with conventional TILs
• Uncovering clinical potential as a novel TIL product with enhanced safety and efficacy
